HIV Policy & Advocacy
U.S. Preventive Services Task Force Recommends Routine HIV Screening for Adolescents and Adults
- Details
- Category: HIV Testing & Diagnosis
- Published on Friday, 03 May 2013 00:00
- Written by Liz Highleyman
On April 30 the U.S. Preventive Services Task Force (USPSTF) issued a "Grade A," or highest-level, recommendation that all adolescents and adults ages 15 through 65 years should receive routine HIV screening. "These recommendations...reinforce the importance of people everywhere knowing their HIV status and, if positive, accessing care, receiving treatment and other prevention services," said CDC's Jonathan Mermin.
CROI 2013: Second-line NRTI-sparing HIV Regimen Proves Equally Effective
- Details
- Category: HIV Treatment
- Published on Wednesday, 20 March 2013 00:00
- Written by Keith Alcorn
A second-line antiretroviral regimen of lopinavir/ritonavir (Kaletra or Aluvia) and raltegravir (Isentress) proved just as effective as a regimen containing lopinavir/ritonavir and 2 or 3 nucleoside or nucleotide analogs in large study conducted in Australia, Africa, Latin America, and Asia, researchers from Sydney’s Kirby Institute reported this week at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.
CROI 2013: HIV+ People Less Likely to Use Aspirin to Prevent Heart Attacks, and May Benefit Less [VIDEO]
- Details
- Category: HIV-Related Conditions
- Published on Friday, 15 March 2013 00:00
- Written by Gregory Fowler
People with HIV were less likely than HIV negative people to use daily aspirin to prevent heart attacks, but among those who did, aspirin did not appear to reduce the risk of myocardial infarction (MI), researchers reported last week at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.
CROI 2013: Small Risk of Birth Defects Due to Efavirenz Confirmed in French Cohort
- Details
- Category: HIV Treatment
- Published on Wednesday, 20 March 2013 00:00
- Written by Keith Alcorn
A large French study has found an elevated risk of some birth defects in children born to women exposed to some antiretroviral drugs during the first trimester of pregnancy, French researchers reported on at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) this month in Atlanta.
CROI 2013: New Pro-drug Tenofovir Alafenamide Appears Equally Effective but Better Tolerated
- Details
- Category: HIV Treatment
- Published on Thursday, 07 March 2013 00:00
- Written by Liz Highleyman
Tenofovir alafenamide fumarate, or TAF (formerly GS-7340), a new pro-drug of the widely used NRTI tenofovir, reaches cells harboring HIV more easily than the older disoproxil fumarate (TDF), allowing for similar antiviral efficacy with smaller doses and with less adverse effect on kidneys and bones,researchers reported Tuesday at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.
More Articles...
- CROI 2013: Can People with Resistant HIV Omit NRTIs When Switching to a New Regimen? [VIDEO]
- CROI 2013: New Tenofovir Alafenamide Looks Easier on Kidneys [VIDEO]
- CROI 2013: Pipeline Antiretrovirals Promise More Effective and Better Tolerated HIV Treatment
- CROI 2013: Health Insurance Coverage Linked to HIV Viral Load Suppression [VIDEO]
Web Design and Development by